Researchers studied pharmacokinetics of morphine in SCD using USCPACK software. Results showed that morphine clearance in SCD patients was 3-10 times higher than published estimates for the non-SCD population. SCD patients had correspondingly lower AUC and half-life of morphine.
The authors suggest an increased clearance of morphine in SCD patients may arise from increased hepatic and renal blood flow, and may cause their requirement of a higher dose and frequency of morphine to achieve optimal analgesia.
Read The Journal of Pain abstract on morphine for sickle cell disease patients.
Related Articles on Pain Management:
Florida County Rethinks Painkiller Legislation After Statewide Restrictions Are Passed
Maine Painkiller Bill Faces Opposition
85% of Washington Residents Say They or Loved Ones Are Experiencing Pain
At the Becker’s 32nd Annual Meeting: The Business and Operations of ASCs, taking place October 29-31 in Chicago, ASC leaders, surgeons and healthcare executives will explore strategies to drive growth, enhance operational performance, navigate reimbursement challenges and prepare for the future of ambulatory surgery. Apply for complimentary registration now.